About: Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage
Creator	María, & Fernández-Cuadros, Marcos Susana Pérez-Moro, Olga Peña-Lora, Daiana Albaladejo-Florín, Jesús
Source	Medline; PMC
abstract	To date, there is no definitive treatment for the new SARS-CoV-2 pandemic. Three evolutionary stages in SARS-CoV-2 infection are recognized (early infection, pulmonary phase, and systemic hyper inflammation), with characteristic clinical signs and symptoms. There are 80 international experimental trials underway seeking effective treatment for the COVID-19 pandemic. Of these, there are only three that consider ozone therapy (major auto hemotherapy) as an alternative option. There is no study that evaluates rectal ozone insufflation, despite being a safe, cheap, risk-free technique. That technique is a systemic route of ozone administration (95–96%) and that could be extrapolated to the use of SARS-CoV-2, given the excellent results observed in the management of Ebola. Ozone has four proven biological properties that could allow its use as an alternative therapy in the different phases of SARS-CoV-2 infection. Ozone could inactivate the virus by direct (O3) or indirect oxidation (ROS and LOPs) and could stimulate the cellular and humoral immune systems, being useful in the early COVID-19 infection phase (stages 1 and 2a). Ozone improves gas exchange, reduces inflammation, and modulates the antioxidant system, so it would be useful in the hyper inflammation or “cytokine storm” phase, and in the hypoxemia and/or multi-organ failure phase (stage 2b and stage 3). Given the current pandemic, it is urgent to carry out an experimental study that confirms or rules out the biological properties of ozone and thus allows it to be an alternative or compassionate therapy for the effective management of SARS-Cov-2 infection. The Ethical Committee at our Hospital has authorized the use of this technique for compassionate management of SARS-CoV-2 infection, considering the four biological Ozone properties exposed previously.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1007/s42399-020-00328-7
bibo:pmid	32838159
has license	no-cc
sha1sum (hex)	45c19e2b1460fd04c44c9a1647e7c75a2934cf8b
schema:url	https://doi.org/10.1007/s42399-020-00328-7
resource representing a document's title	Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage
has PubMed Central identifier	PMC7340747
has PubMed identifier	32838159
schema:publication	SN Compr Clin Med
resource representing a document's body	covid:45c19e2b1460fd04c44c9a1647e7c75a2934cf8b#body_text
is schema:about of	named entity 'management' named entity 'infection' named entity 'Given' named entity 'proven' named entity 'ozone' named entity 'definitive' named entity 'Therapeutic' named entity 'USE OF' named entity 'PROPERTIES' named entity 'COVID-19 PANDEMIC' named entity 'PHASES' named entity 'OZONE' named entity 'CARRY' named entity 'SARS-COV-2' named entity 'COVID-19' named entity 'early' named entity 'pandemic' named entity 'ozone' named entity 'biological' named entity 'hyper' named entity 'Committee' named entity 'extrapolated' named entity 'symptoms' named entity 'current' named entity 'study' named entity 'Ozone' named entity 'Ozone' named entity 'ROS' named entity 'SARS-CoV-2' named entity 'infection' named entity 'antioxidant' named entity 'ozone' named entity 'infection' named entity 'gas exchange' named entity 'alternative therapy' named entity 'infection' named entity 'Ozone' named entity 'biological properties' named entity 'SARS-Cov-2' named entity 'SARS-CoV-2' named entity 'multi-organ failure' named entity 'Ozone' named entity 'Three' named entity 'hemogram' named entity 'immunomodulatory' named entity 'oxygen' named entity 'neutrophils' named entity 'Norwalk virus' named entity 'ROS' named entity 'proinflammatory cytokines' named entity 'superoxide' named entity 'oxygen' named entity 'radiography' named entity 'virus' named entity 'fungicidal' named entity 'antiparasitic' named entity 'COVID-19' named entity 'lymphopenia' named entity 'renal failure' named entity 'lung' named entity 'bactericidal' named entity 'tumor necrosis factor-α' named entity 'MCP-1' named entity 'antiparasitic' named entity 'inflammatory cytokines' named entity 'fulminant' named entity 'TNF-α' named entity 'coagulation disorders' named entity 'ozone' named entity 'erythroid' named entity 'MERS-CoV' named entity 'antiphospholipid syndrome' named entity 'Wuhan' named entity 'multi-organ failure' named entity 'infection' named entity 'neutrophilia' named entity 'common cold'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software